Death receptor-dependent apoptosis and cell cycle delay induced by bioymifi in human cervical cancer cells


ALTUN A., ŞAHİN İNAN Z. D., YULAK F.

PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.35, no.4, pp.1031-1036, 2022 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.36721/pjps.2022.35.4.reg.1031-1036.1
  • Journal Name: PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1031-1036
  • Keywords: &nbsp, Apoptosis, bioymifi, cell cycle, cervical cancer, death receptor, TRAIL
  • Sivas Cumhuriyet University Affiliated: Yes

Abstract

In chemotherapy applied against cervical cancer, non-specific cytotoxicity and drug resistance that develops over time are trying to be overcome. Therefore, the development of effective and innovative chemotherapeutic drugs for the treatment is among the priority issues in the medical field. The anticancer activity of the Bioymifi, which can activate apoptosis by inducing DR-5 clustering and aggregation against the human cervical cancer cell line, was investigated in the current study. The cytotoxic activity of Bioymifi on the HeLa cell line was identified using XTT assay. The pathway of the cell death mechanism was analyzed through the cell cycle and Annexin V assays by the flow cytometry. DAPI staining assay was applied under fluorescence microscopy to examine the nuclear morphology. Bioymifi appeared to have a remarkable IC50 value (11.75??M) against HeLa cells. The cell cycle analysis demonstrated the increase of Bioymifi cured HeLa cells in the S phase. And also, 11.75??M of Bioymifi caused a significantly higher apoptotic effect compared to control. In addition, in vitro immunofluorescence experiments of this study represented that Bioymifi reduced Ki-67 localization in HeLa cells. Bioymifi has significantly anticancer actions in Human cervix cancer in vitro and can be combined with standard treatment.